Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.
about
Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancerManagement of relapsed ovarian cancer: a reviewClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerTreatment options in recurrent ovarian cancer: latest evidence and clinical potential.A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group studyDevelopment of nanoscale approaches for ovarian cancer therapeutics and diagnosticsThe role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trialsA phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancerOutcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage eraIntroduction to managing patients with recurrent ovarian cancerClinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancerCarboplatin and Liposomal Doxorubicin for Ovarian Cancer.Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.Survival and Control Prognosticators of Recurrent Gynecological Malignancies of the Pelvis and Para-aortic Region Treated with Stereotactic Body Radiation Therapy.Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer.Nanomedicine: a pharma perspective.The next steps in improving the outcomes of advanced ovarian cancer.Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer.Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomes.Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer.The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).Discussion: session 2.Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO AA review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: A case report.Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy.Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer.Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
P2860
Q24201282-262AF6CB-E710-499D-9B12-5FCE64DE2B78Q26741755-0D57A7F8-96C8-492F-ABA4-5A99232973F7Q27024235-350EF7E2-C4F7-4E87-B870-9AA3C0DC6838Q27692699-47E8E359-A002-4170-8059-A2185DF80CA4Q30277998-EC94CCC1-F1D4-486D-8496-A0754A8EC51FQ30421664-5DBBAF63-E44D-46F1-B65E-4C771FD83473Q33409319-7FBA6FCD-E754-4BD2-92E9-6CDEC665D932Q33411202-B941A6CA-A014-4778-BAB5-1B42B68992DAQ34045769-1F289832-1A84-47EA-A3C5-0B5B235BE313Q36382341-AC533434-6290-4BC7-98E1-60B4D28662C5Q36728989-4964F120-DB2D-4888-9FC2-EC0D0E4BB905Q37016053-0E8310D7-26B8-46C2-AD31-BC28DDD7E261Q37193617-AC9D08DD-B77A-4BF8-8989-1C41B2F0DE7AQ37427531-97FEFA82-E431-479F-AEEA-D3D0626F6ED1Q37553978-9E342A98-27D3-484B-99C3-14484B8798A2Q37745944-34CB9927-1AF6-40E1-B2CC-9BB13F259B3FQ38246663-4ABC4A52-234A-4F2C-B986-1F6CFD9DA73BQ38535374-5CF26130-9409-4017-9665-778CCC7C6AC6Q38769834-D9607CC7-51BB-4C87-B4C7-C630D060ECF8Q38948775-43D67A2A-D9C3-44DF-8A78-4713D9B3C544Q38969949-47890296-65CA-4AAF-A713-BBE8D18E0E41Q39282981-F80888FE-8D49-4D47-9755-90F85854DD5FQ40251231-D5EF6AD6-0183-40D4-8AD9-9C3D832F1E82Q41012742-C823FE96-4CE7-4C06-87C6-BBDB9AF90523Q46190587-9883E83E-EB21-4F2C-A146-27442E5FE5FCQ47306372-14C23AAF-21FD-4A19-82E3-74FC480774A4Q47631494-8EA09785-713F-4192-B584-EDF2657F921BQ47861842-94FD6AF7-60C3-42F8-9FDE-3DB41421156FQ48333179-0EDFC43C-71E4-4227-A5F5-17B9DE555F7CQ52887388-DEA47FCB-F77C-4806-B1B3-21ADE11B9A87Q54951150-783E488D-EDCC-44B2-B2D3-5F4FE3147114Q59125756-E33B5D27-4CA1-48A4-BF21-B02DDDC0BF61
P2860
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Final overall survival results ...... itive ovarian cancer patients.
@ast
Final overall survival results ...... itive ovarian cancer patients.
@en
type
label
Final overall survival results ...... itive ovarian cancer patients.
@ast
Final overall survival results ...... itive ovarian cancer patients.
@en
prefLabel
Final overall survival results ...... itive ovarian cancer patients.
@ast
Final overall survival results ...... itive ovarian cancer patients.
@en
P2093
P2860
P356
P1476
Final overall survival results ...... itive ovarian cancer patients.
@en
P2093
E P Lauraine
M C Piccirillo
R Largillier
T Bonaventura
P2860
P2888
P304
P356
10.1038/BJC.2012.307
P407
P50
P577
2012-07-26T00:00:00Z